| Code | Description | Claims | Beneficiaries | Total Paid |
| 99283 |
|
15,593 |
14,704 |
$1.77M |
| 99284 |
|
11,068 |
9,921 |
$1.25M |
| 96361 |
|
3,538 |
2,719 |
$1.10M |
| 99285 |
|
4,516 |
4,005 |
$580K |
| 97110 |
|
6,453 |
1,749 |
$474K |
| 92507 |
|
5,788 |
1,834 |
$436K |
| 97530 |
|
4,025 |
1,336 |
$348K |
| 99282 |
|
2,452 |
2,320 |
$258K |
| 74177 |
|
916 |
762 |
$246K |
| 80053 |
|
15,631 |
13,930 |
$181K |
| 96365 |
|
976 |
589 |
$179K |
| 70450 |
|
612 |
528 |
$151K |
| 99213 |
|
1,279 |
1,156 |
$129K |
| 96360 |
|
548 |
416 |
$110K |
| 74176 |
|
281 |
233 |
$77K |
| 85025 |
|
21,181 |
18,164 |
$74K |
| 99281 |
|
857 |
830 |
$74K |
| 84443 |
|
4,589 |
4,170 |
$73K |
| 94640 |
|
815 |
510 |
$69K |
| 96366 |
|
419 |
257 |
$62K |
| 99214 |
|
599 |
549 |
$59K |
| 87502 |
|
2,412 |
2,198 |
$43K |
| 36415 |
|
15,511 |
13,276 |
$42K |
| 80061 |
|
3,090 |
2,902 |
$41K |
| G0378 |
Hospital observation service, per hour |
635 |
314 |
$39K |
| 99211 |
|
484 |
366 |
$38K |
| 97016 |
|
901 |
233 |
$33K |
| 97140 |
|
1,264 |
426 |
$31K |
| 71046 |
|
1,510 |
1,382 |
$29K |
| 83036 |
|
2,217 |
2,050 |
$29K |
| U0002 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc |
4,091 |
3,792 |
$27K |
| 82306 |
|
1,153 |
1,061 |
$24K |
| 73564 |
|
532 |
467 |
$23K |
| 80048 |
|
2,431 |
1,961 |
$22K |
| 87088 |
|
1,887 |
1,640 |
$21K |
| 77063 |
|
435 |
401 |
$21K |
| 43239 |
|
50 |
41 |
$18K |
| 80307 |
|
1,095 |
923 |
$18K |
| 71275 |
|
52 |
41 |
$17K |
| 73630 |
|
559 |
507 |
$16K |
| 82607 |
|
849 |
771 |
$15K |
| 73130 |
|
489 |
418 |
$14K |
| 73030 |
|
392 |
348 |
$13K |
| 87491 |
|
389 |
342 |
$13K |
| 97161 |
|
267 |
250 |
$12K |
| 86803 |
|
469 |
433 |
$12K |
| 73610 |
|
427 |
381 |
$11K |
| 59025 |
|
127 |
64 |
$10K |
| 97162 |
|
253 |
223 |
$10K |
| 84439 |
|
502 |
459 |
$10K |
| 93005 |
|
3,603 |
3,155 |
$9K |
| 87651 |
|
1,243 |
1,098 |
$9K |
| 84484 |
|
3,479 |
2,485 |
$9K |
| 87389 |
|
360 |
331 |
$7K |
| 84466 |
|
609 |
556 |
$6K |
| 83735 |
|
3,105 |
2,450 |
$6K |
| 97112 |
|
452 |
151 |
$6K |
| 87591 |
|
389 |
342 |
$6K |
| 77067 |
|
436 |
402 |
$6K |
| 62323 |
|
12 |
12 |
$5K |
| 73110 |
|
175 |
158 |
$5K |
| 83540 |
|
619 |
564 |
$5K |
| 82728 |
|
304 |
281 |
$5K |
| 81001 |
|
6,819 |
6,163 |
$5K |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
527 |
426 |
$5K |
| 86780 |
|
177 |
161 |
$4K |
| 86140 |
|
1,035 |
821 |
$4K |
| 81514 |
|
55 |
53 |
$4K |
| 82746 |
|
415 |
381 |
$4K |
| 87661 |
|
242 |
205 |
$4K |
| 87086 |
|
246 |
238 |
$4K |
| 76705 |
|
54 |
44 |
$4K |
| 87186 |
|
559 |
470 |
$4K |
| 71045 |
|
1,506 |
1,287 |
$3K |
| 84153 |
|
231 |
211 |
$3K |
| U0004 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r |
17 |
17 |
$3K |
| 81003 |
|
1,638 |
1,414 |
$3K |
| 82570 |
|
321 |
288 |
$3K |
| 85610 |
|
1,745 |
1,479 |
$3K |
| 70551 |
|
12 |
12 |
$3K |
| 85652 |
|
606 |
524 |
$2K |
| J3490 |
Unclassified drugs |
1,556 |
765 |
$2K |
| 72100 |
|
60 |
57 |
$2K |
| 86850 |
|
125 |
103 |
$2K |
| 96374 |
|
3,797 |
3,250 |
$2K |
| 84703 |
|
2,309 |
1,909 |
$2K |
| 85027 |
|
251 |
207 |
$2K |
| 73502 |
|
63 |
57 |
$2K |
| 82565 |
|
489 |
350 |
$2K |
| 83690 |
|
2,606 |
2,137 |
$2K |
| 83880 |
|
824 |
694 |
$2K |
| 83605 |
|
1,399 |
1,084 |
$2K |
| 71250 |
|
17 |
13 |
$2K |
| 87340 |
|
66 |
64 |
$1K |
| 82043 |
|
216 |
205 |
$1K |
| G0463 |
Hospital outpatient clinic visit for assessment and management of a patient |
64 |
51 |
$1K |
| 85730 |
|
1,717 |
1,438 |
$1K |
| 96372 |
|
2,048 |
1,622 |
$1K |
| 96375 |
|
2,805 |
2,051 |
$1K |
| 82248 |
|
676 |
543 |
$1K |
| 84702 |
|
65 |
42 |
$1K |
| 80051 |
|
273 |
184 |
$1K |
| 82150 |
|
621 |
502 |
$1K |
| 82947 |
|
317 |
222 |
$1K |
| 86900 |
|
128 |
104 |
$1K |
| 73562 |
|
46 |
41 |
$1K |
| 92523 |
|
12 |
12 |
$996.54 |
| J7030 |
Infusion, normal saline solution , 1000 cc |
1,696 |
1,201 |
$960.35 |
| 84520 |
|
470 |
347 |
$835.83 |
| 86038 |
|
28 |
25 |
$821.21 |
| 96376 |
|
521 |
294 |
$762.52 |
| 73080 |
|
31 |
29 |
$680.10 |
| 86901 |
|
128 |
104 |
$674.05 |
| 88305 |
|
1,355 |
297 |
$614.06 |
| 84550 |
|
106 |
94 |
$610.53 |
| 99204 |
|
15 |
13 |
$559.67 |
| 74018 |
|
13 |
12 |
$559.18 |
| 87077 |
|
497 |
288 |
$498.39 |
| 85018 |
|
24 |
24 |
$420.16 |
| 77003 |
|
570 |
485 |
$401.34 |
| 72125 |
|
19 |
14 |
$378.48 |
| 85379 |
|
513 |
443 |
$336.98 |
| 90715 |
|
13 |
12 |
$283.10 |
| 82550 |
|
61 |
49 |
$227.08 |
| 87070 |
|
57 |
43 |
$216.70 |
| J1170 |
Injection, hydromorphone, up to 4 mg |
704 |
420 |
$160.26 |
| 84481 |
|
17 |
13 |
$146.09 |
| 80076 |
|
13 |
13 |
$120.59 |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
2,448 |
1,977 |
$118.30 |
| 87634 |
|
329 |
266 |
$116.10 |
| J2270 |
Injection, morphine sulfate, up to 10 mg |
594 |
397 |
$108.78 |
| J2550 |
Injection, promethazine hcl, up to 50 mg |
347 |
246 |
$100.17 |
| J7120 |
Ringers lactate infusion, up to 1000 cc |
1,253 |
1,005 |
$57.16 |
| Q0162 |
Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen |
628 |
506 |
$52.78 |
| 87205 |
|
37 |
25 |
$45.38 |
| J1200 |
Injection, diphenhydramine hcl, up to 50 mg |
419 |
311 |
$28.92 |
| J1815 |
Injection, insulin, per 5 units |
19 |
12 |
$25.16 |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
1,870 |
1,369 |
$24.12 |
| 84156 |
|
12 |
12 |
$20.14 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
541 |
421 |
$16.00 |
| J2704 |
Injection, propofol, 10 mg |
984 |
819 |
$15.87 |
| J7040 |
Infusion, normal saline solution, sterile (500 ml = 1 unit) |
361 |
223 |
$6.58 |
| J2765 |
Injection, metoclopramide hcl, up to 10 mg |
172 |
113 |
$5.87 |
| J3360 |
Injection, diazepam, up to 5 mg |
14 |
14 |
$5.45 |
| J0665 |
Injection, bupivicaine, not otherwise specified, 0.5 mg |
215 |
168 |
$5.12 |
| J7512 |
Prednisone, immediate release or delayed release, oral, 1 mg |
291 |
224 |
$5.05 |
| J0131 |
Injection, acetaminophen, not otherwise specified,10 mg |
63 |
59 |
$5.00 |
| J3010 |
Injection, fentanyl citrate, 0.1 mg |
345 |
262 |
$3.64 |
| J1596 |
Injection, glycopyrrolate, 0.1 mg |
120 |
110 |
$3.53 |
| J7620 |
Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme |
209 |
144 |
$3.30 |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
168 |
39 |
$2.18 |
| J2003 |
Injection, lidocaine hydrochloride, 1 mg |
99 |
77 |
$2.07 |
| J2001 |
Injection, lidocaine hcl for intravenous infusion, 10 mg |
191 |
156 |
$0.92 |
| J7613 |
Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg |
33 |
26 |
$0.58 |
| J2250 |
Injection, midazolam hydrochloride, per 1 mg |
223 |
188 |
$0.53 |
| J1940 |
Injection, furosemide, up to 20 mg |
27 |
13 |
$0.05 |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
2,003 |
1,596 |
$0.00 |
| J3301 |
Injection, triamcinolone acetonide, not otherwise specified, 10 mg |
180 |
156 |
$0.00 |
| Q9966 |
Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml |
38 |
38 |
$0.00 |
| G1004 |
Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program |
18 |
14 |
$0.00 |
| J1171 |
Injection, hydromorphone, 0.1 mg |
45 |
35 |
$0.00 |
| A9270 |
Non-covered item or service |
762 |
102 |
$0.00 |
| J0690 |
Injection, cefazolin sodium, 500 mg |
95 |
72 |
$0.00 |
| 00813 |
|
12 |
12 |
$0.00 |
| 82803 |
|
70 |
55 |
$0.00 |
| 90471 |
|
13 |
12 |
$0.00 |
| J2060 |
Injection, lorazepam, 2 mg |
18 |
12 |
$0.00 |